Author + information
- Daniel J. Lenihan, MDa,∗ (, )@DLenihanICOS_MD,
- Michael G. Fradley, MDb,
- Susan Dent, MDc,
- Christine Brezden-Masley, MD, PhDd,
- Joseph Carver, MDe,f,
- Roberto Kalil Filho, MD, PhDg,
- Tomas G. Neilan, MD, MPHh,
- Anne Blaes, MDi,
- Chiara Melloni, MD, MHSj,
- Joerg Herrmann, MDk,
- Saro Armenian, DO, MPHl,
- Paaladinesh Thavendiranathan, MD, SMm,
- Gregory T. Armstrong, MD, MSCEn,
- Bonnie Ky, MD, MSCEe,f and
- Ludhmila Hajjar, MDg@ludhmilahajjar
- aCardio-Oncology Center of Excellence, Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri
- bCardio-Oncology Program, Moffitt Cancer Center, University of South Florida, Tampa, Florida
- cDuke Cancer Institute, Duke University School of Medicine, Durham, North Carolina
- dMount Sinai Hospital, University of Toronto, Toronto, Canada
- eCardio-Oncology Center of Excellence at the Abramson Cancer Center, Division of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- fCardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- gCardio-Oncology Program, Department of Cardiopneumology, Cancer Institute and Heart Institute, University of São Paulo, Brazil
- hCardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- iDivision of Hematology/Oncology, University of Minnesota, Minneapolis, Minnesota
- jDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- kDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
- lCity of Hope Comprehensive Cancer Center, Duarte, California
- mDivision of Cardiology, Peter Munk Cardiac Centre, Ted Rogers Program in Cardiotoxicity Prevention, University Health Network, University of Toronto, Toronto, Canada
- nDepartment of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, Tennessee
- ↵∗Address for correspondence:
Dr. Daniel J. Lenihan, Cardiovascular Division, Washington University in St. Louis, 660 South Euclid Avenue, Campus Box 8086, St Louis, Missouri 63110.
• The discipline of cardio-oncology has enjoyed extensive and complex development at a breathtaking pace.
• Extensive ongoing clinical and basic research continue to shape and formulate the practice of cardio-oncology.
• The path forward for the field needs to be centered on excellence in clinical care, transformative research, and broad education principles.
The discipline of cardio-oncology has expanded at a remarkable pace. Recent developments and challenges to clinicians who practice cardio-oncology were presented at the Global Cardio-Oncology Summit on October 3 to 4, 2019, in São Paulo, Brazil. Here, we present the top 10 priorities for our field that were discussed at the meeting, and also detail a potential path forward to address these challenges. Defining robust predictors of cardiotoxicity, clarifying the role of cardioprotection, managing and preventing thromboembolism, improving hematopoietic stem cell transplant outcomes, personalizing cardiac interventions, building the cardio-oncology community, detecting and treating cardiovascular events associated with immunotherapy, understanding tyrosine kinase inhibitor cardiotoxicity, and enhancing survivorship care are all priorities for the field. The path forward requires a commitment to research, education, and excellence in clinical care to improve our patients' lives.
- antiangiogenic therapy
- bone marrow transplantation
- breast cancer
- cancer survivorship
- tyrosine kinase inhibitor
Dr. Lenihan has received research support from Myocardial Solutions, Inc.; and has received consulting fees from Pfizer, Roche, Acorda, Bristol-Myers Squibb, Lilly, and Prothena. Dr. Fradley has received research grant support from Medtronic. Dr. Dent has received honoraria from Novartis Canada. Dr. Neilan has received consulting fees from H3-Biomedicine, Bristol-Myers Squibb, Parexel, Aprea Therapeutics, and Intrinsic Imaging. Dr. Melloni has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Ferring Pharmaceuticals, GlaxoSmithKline, Intra-Cellular Therapies, Luitpold Pharmaceuticals, Merck and Co., Roche Group, Sanofi, St. Jude Medical, and Pfizer. Dr. Ky has received research support from the NIH; and has received consulting support from Bristol-Myers Squibb. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Anju Nohria, MD, served as Guest Editor for this paper.
- Received October 22, 2019.
- Accepted November 4, 2019.
- 2019 The Authors
- Central Illustration
- Defining Robust Predictors of Cardiotoxicity
- Clarifying the Role of Cardioprotection
- Managing and Preventing Thromboembolic Events in Patients With Cancer
- Improving CV Outcomes in Stem Cell Transplantation
- Personalizing Cardiovascular Interventions
- Building the Community
- Detecting and Treating Adverse CV Events Associated With Immunotherapy
- Understanding Multi-targeted TKI Cardiotoxicity
- Enhancing Survivorship Care
- Advancing the Field of Cardio-Oncology